Press release
Angioedema Market to Reach USD 7.9 Billion by 2034
Angioedema
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71681
While antihistamines, corticosteroids, and epinephrine are often used in acute allergic angioedema, hereditary angioedema (HAE) has unique treatment pathways involving C1 esterase inhibitors, bradykinin B2 receptor antagonists, and kallikrein inhibitors. Growing awareness, improved diagnostic tools, and the approval of novel therapies are significantly transforming the market outlook. Between 2024 and 2034, the global angioedema market is expected to expand steadily, driven by innovation and patient advocacy.
Market Overview
The global Angioedema market size in 2024 is estimated at USD 4.2 billion and is projected to reach USD 7.9 billion by 2034, growing at a CAGR of 6.8% (2024-2034).
Key highlights:
• Rising prevalence of drug-induced and idiopathic angioedema worldwide.
• Expanding therapeutic pipeline for hereditary angioedema (HAE) patients.
• Growing use of self-administered and prophylactic therapies.
• Increasing rare disease awareness programs and advocacy networks.
• Challenges include high costs of biologics, limited awareness in developing regions, and diagnosis delays.
Leading companies such as Takeda, CSL Behring, BioCryst Pharmaceuticals, and Pharming Group are actively driving innovation in the angioedema treatment space.
Segmentation Analysis
The angioedema market can be segmented as follows:
• By Product
o Antihistamines
o Corticosteroids
o Epinephrine
o C1 esterase inhibitors
o Kallikrein inhibitors
o Bradykinin B2 receptor antagonists
o Monoclonal antibodies
• By Platform
o Small molecules
o Biologics
o RNA-based drugs
o Gene therapies
• By Technology
o Protein replacement therapy
o Antibody engineering
o RNA interference (RNAi)
o Gene-editing technologies
• By End Use
o Hospitals
o Specialty clinics
o Homecare settings
• By Application
o On-demand treatment
o Prophylactic treatment
o Research applications
Segmentation Summary:
For acute allergic angioedema, antihistamines, corticosteroids, and epinephrine dominate. However, in hereditary angioedema, the focus is shifting toward long-term prophylactic treatments, particularly subcutaneous therapies and monoclonal antibodies. Homecare settings are gaining popularity due to the growing availability of self-injectable drugs.
Explore Full Report here: https://exactitudeconsultancy.com/reports/71681/angioedema-market
Regional Analysis
• North America
Largest market in 2024, owing to advanced healthcare infrastructure, strong patient advocacy groups, and widespread adoption of novel biologics.
• Europe
Second-largest market, supported by orphan drug designations, growing genetic testing adoption, and major pharma presence in Germany, France, and the UK.
• Asia-Pacific
Fastest-growing region, with increasing prevalence of ACE inhibitor-induced angioedema, rising rare disease awareness, and expanding pharma investments in Japan, China, and India.
• Middle East & Africa
Growth remains limited due to diagnostic challenges and affordability barriers, though partnerships with international players are improving patient access.
• Latin America
Brazil and Mexico lead growth, supported by emerging healthcare programs, though reimbursement challenges persist.
Regional Summary:
North America and Europe dominate revenues, but Asia-Pacific is expected to post the highest CAGR through 2034, making it a key strategic focus for global biopharma companies.
Market Dynamics
Key Growth Drivers
• Increasing Prevalence: Rising cases of drug-induced and hereditary angioedema.
• Pipeline Expansion: Next-generation kallikrein inhibitors and monoclonal antibodies under development.
• Supportive Regulatory Pathways: Orphan drug designations and fast-track approvals.
• Improved Awareness: Advocacy programs driving early diagnosis and patient education.
Key Challenges
• High Cost of Therapies: Biologics and orphan drugs remain expensive.
• Regional Disparities: Limited infrastructure in low-income economies.
• Treatment Adherence: Chronic management requires continuous therapy, impacting compliance.
• Safety Concerns: Long-term effects of novel therapies still under investigation.
Latest Trends
• Shift toward self-administered subcutaneous therapies.
• Growing focus on prophylactic treatments for HAE patients.
• Research into RNA-based and gene-editing therapies for long-term solutions.
• AI-driven patient monitoring tools for better disease management.
• Strategic collaborations between biotech and pharma to accelerate commercialization.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71681
Competitor Analysis
Major players in the angioedema market include:
• Takeda Pharmaceutical Company Limited
• CSL Behring
• BioCryst Pharmaceuticals
• Pharming Group N.V.
• Ionis Pharmaceuticals
• KalVista Pharmaceuticals
• Adverum Biotechnologies
• Intellia Therapeutics
• Pharvaris
• Sanofi
Competitive Summary:
Takeda leads with its robust HAE portfolio, while CSL Behring and Pharming continue to dominate with C1 esterase inhibitors and recombinant therapies. BioCryst has made notable advances in oral prophylactic kallikrein inhibitors, and Ionis is driving RNA-based innovation. Emerging players like Pharvaris and Intellia are exploring gene-editing and next-generation biologics, intensifying competition.
Conclusion
The global angioedema market is projected to grow from USD 4.2 billion in 2024 to USD 7.9 billion by 2034, at a CAGR of 6.8%.
Future growth will be driven by next-generation prophylactic therapies, patient-friendly formulations, and genetic innovation. While high costs and limited awareness pose challenges, the expanding therapeutic pipeline and rising prevalence will ensure continued momentum.
Key Takeaway: The angioedema market is evolving rapidly, with a shift from acute management to long-term preventive care. Companies investing in affordability, accessibility, and innovative biologics will be well-positioned to lead through 2034.
This report is also available in the following languages : Japanese (血管性浮腫市場), Korean (혈관부종 시장), Chinese (血管性水肿市场), French (Marché de l'angio-œdème), German (Angioödem-Markt), and Italian (Mercato dell'angioedema), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71681/angioedema-market#request-a-sample
Our More Reports:
Cataract Surgery Complications Market
https://exactitudeconsultancy.com/reports/72247/cataract-surgery-complications-market
Central Serous Chorioretinopathy Market
https://exactitudeconsultancy.com/reports/72248/central-serous-chorioretinopathy-market
Centronuclear Myopathy Market
https://exactitudeconsultancy.com/reports/72249/centronuclear-myopathy-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Angioedema Market to Reach USD 7.9 Billion by 2034 here
News-ID: 4175811 • Views: …
More Releases from Exactitude Consultancy
Idiopathic CD4 Lymphocytopenia (ICL) Market Detailed Industry Report Analysis 20 …
Introduction
Idiopathic CD4 lymphocytopenia (ICL) is a rare, acquired immune disorder characterized by persistently low CD4+ T-cell counts without evidence of HIV infection or other known immunodeficiencies. CD4 T-cells play a critical role in immune defense, and their deficiency leaves patients highly susceptible to opportunistic infections, malignancies, and autoimmune complications.
Since its first description in the 1990s, ICL has remained poorly understood, with its etiology still unclear. The rarity and diagnostic challenges…
Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID) Market to Reach …
Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID), also known as "bubble boy disease," is an ultra-rare genetic disorder caused by mutations in the ADA gene, leading to the absence of the adenosine deaminase enzyme. This results in toxic metabolite buildup and severe impairment of the immune system. Without treatment, infants with ADA-SCID typically do not survive beyond the first year of life.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71679
For…
Laband Syndrome Market Detailed Industry Report Analysis 2025-2034
Introduction
Laband syndrome, also known as Zimmermann-Laband syndrome (ZLS), is an ultra-rare genetic disorder characterized by gingival fibromatosis (severe gum overgrowth), distinctive craniofacial features, hypertrichosis, hepatosplenomegaly, and skeletal abnormalities such as hypoplastic nails, shortened distal phalanges, and joint hyperextensibility. The disorder has been associated with mutations in KCNH1 and ATP6V1B2 genes, which play roles in cellular signaling and ion channel regulation.
Because of its extreme rarity, Laband syndrome poses significant diagnostic and…
Wilson Disease Market is expected to reach USD 4.6 billion by 2034
Wilson Disease is a rare autosomal recessive genetic disorder caused by mutations in the ATP7B gene, leading to impaired copper metabolism. Excessive copper accumulation in the liver, brain, and other organs results in hepatic, neurological, and psychiatric manifestations. The estimated global prevalence is about 1 in 30,000 individuals, though diagnosis often remains delayed due to variable symptoms.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71677
Historically, treatment has relied on…
More Releases for Angioedema
Hereditary Angioedema Market: An In-Depth Analysis
In 2024, the market for Hereditary Angioedema Market was valued at USD 3.1 billion. It is anticipated to grow to USD 5.9 billion by 2033, with a CAGR of 6.82% over the period 2026-2033.
Hereditary Angioedema Market Overview
The global hereditary angioedema therapeutics market is experiencing significant expansion, driven by increasing awareness, improved diagnostic capabilities, and the introduction of novel treatment options. Advances in genetic research have enabled early and accurate…
Hereditary Angioedema Market Research Report 2032
DelveInsight's "Hereditary Angioedema Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the Hereditary Angioedema, historical and forecasted epidemiology as well as the Hereditary Angioedema market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Hereditary Angioedema (HAE) is a rare genetic disorder caused by the deficiency in functional C1 inhibitor (C1INH) that results in recurrent attacks of localized subcutaneous or…
Hereditary Angioedema - Drug Pipeline Landscape, 2022
Global Hereditary Angioedema Market report from Global Insight Services is the single authoritative source of intelligence on hereditary angioedema market. The report will provide you with analysis of impact of latest market disruptions such as Russia-Ukraine war and Covid-19 on the market. Report provides qualitative analysis of the market using various frameworks such as Porters' and PESTLE analysis. Report includes in-depth segmentation and market size data by categories, product types,…
Hereditary Angioedema - Drug Pipeline Landscape, 2022
Hereditary Angioedema is an infrequent inherited disease that causes substantial swelling in various body tissues, such as the abdomen or face caused by a low level or improper function of a protein called the C1 inhibitor. There are three types of hereditary angioedema namely type I, II, and III.
Hereditary Angioedema is mainly caused by a low level or improper function of a protein called the C1 inhibitor.
Read more about Hereditary…
Angioedema Treatment Market 2022 | Detailed Report
This report provides an informative view about the competitive aspect of the global market. It includes detailed picture of the exhibition of a portion of the essential global players working in the Angioedema Treatment market. The research study also provides historical record with profits predictions and forecasts from 2022 to 2028. Also, the business manufacturing of the notable manufacturers is also emphasized with technical data in the report.
This report is…
Hereditary Angioedema Therapeutics Market - Forecast to 2026
As per the research conducted by GME, the Global Hereditary Angioedema Therapeutics Market will grow with a CAGR value of 8.2%. Population growth, as well as lifestyle changes, improved insurance programs, and increased efforts by pharmaceutical and biotechnology companies to develop new products and solutions for the industry, are expected to fuel market revenue for Hereditary Angioedema in the years ahead.
Browse 153 Market Data Tables and 113 Figures spread through…
